Macular degeneration drug approved

Share this article:

The Food and Drug Administration recently approved a drug for the treatment of the wet form of age-related macular degeneration. The medication is called Eylea. The medication is manufactured by Regeneron Pharmaceuticals. At $1,850 per injection, it costs $1000 less than Genentech's Lucentis. Macular degeneration is the leading cause of severe vision loss among residents in senior living settings.


Share this article:
close

Next Article in Products

More in Products

Malnutrition remains issue

Identifying malnutrition in patients upon admission to a hospital is a low-cost way to improve patient outcomes and reduce readmissions, a new report says. Alleviating Hospital-Based Malnutrition: A Baseline Progress Report is an assessment of hospital-based malnutrition released in connection with the first anniversary of ...

Construction Specialties introduces wall and door protection

Construction Specialties introduces wall and door protection

Construction Specialties Inc. (C/S) has debuted a new line of wall and door protection, Acrovyn by Design and Acrovyn Doors by Design. The products embed high-resolution images and logos as ...

BioSensics launches ActivePERS fall detection

BioSensics launches ActivePERS fall detection

BioSensics has introduced ActivePERS, a personal emergency response and telemonitoring solution for seniors.